Intellia Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NTLA research report →
Range $8 – $30
Price Chart
About the company
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs.
- CEO
- John Leonard
- IPO
- 2016
- Employees
- 377
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on NTLA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.40B
- P/E
- -2.92
- Fwd P/E
- 12.29
- PEG
- -0.12
- P/S
- 25.93
- P/B
- 2.23
- EV/EBITDA
- -3.43
- Div Yield
- 0.00%
- Gross Margin
- 84.46%
- Op Margin
- -821.24%
- Net Margin
- -805.75%
- ROE
- -64.73%
- ROIC
- -51.51%
Latest fiscal year · YoY change
- Revenue
- $67.67M+16.9%
- Gross Profit
- $51.75M+8.7%
- Op Income
- $-440,990,000
- Net Income
- $-412,694,000+20.5%
- EPS
- $-3.81+27.4%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $18.48
- 52W Low
- $7.95
- 50D MA
- $11.70
- 200D MA
- $12.89
- Beta
- 1.82
- RSI (14)
- 41
- Avg Volume
- 4.85M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Intellia said Q2 was a major clinical and operational milestone, with lonvo-z on track for a potential 2027 U.S. launch and nex-z enrollment restarted after clinical holds were lifted.· August 6, 2026
- lonvo-z HAELO met its primary and all key secondary endpoints, including an 87% reduction in mean monthly attacks versus placebo over the 6-month primary period.
- 62% of patients in the lonvo-z arm were attack-free and therapy-free, and the company said safety was favorable with only Grade 1/2 AEs and no serious adverse events in the arm at the data cutoff.
- For nex-z, Intellia resumed enrollment and dosing in both Phase III trials in Q2 and said screening is accelerating globally after the clinical holds were resolved.
- The company identified HLA allele C*05:01 as associated with a higher risk of Grade 3+ transaminase elevations in nex-z, and has added HLA typing to trial screening and mitigation protocols.
- Cash, cash equivalents and marketable securities were $628.4 million at June 30, 2026, and management said this should fund operations at least into 2028, excluding product revenues.
Intellia reported collaboration revenue of $7.7 million in Q2 2026 versus $14.2 million in the prior-year quarter. R&D expense was $82.6 million versus $97.0 million a year ago, G&A expense was $37.8 million versus $27.2 million, and net loss was $106.6 million versus $101.3 million in the prior-year quarter. The company ended the quarter with $628.4 million in cash, cash equivalents and marketable securities, up from $605.1 million at December 31, 2025, after completing an April equity financing that yielded approximately $195 million in net proceeds. Management expects the cash balance to fund the company at least into 2028, and said that guidance is conservative because it excludes product revenues. For lonvo-z, management expects FDA acceptance of the BLA by the end of this year and a potential U.S. launch in the first half of 2027. For nex-z, the company said it has resumed enrollment and dosing, that MAGNITUDE has enrolled well over 650 patients, and that the blinded event rate remains within the range internally projected.
John Leonard’s tone was highly confident and promotional around both lead programs. He emphasized that lonvo-z’s Phase III HAELO results position Intellia for a potential first-in-human in vivo gene editing launch next year, while describing nex-z as a potentially differentiated one-time treatment with unusually strong and consistent TTR knockdown. He also framed the HLA finding as a positive step toward precision medicine and said the company is moving quickly to share the information with investigators and patients.
Ed Dulac focused on liquidity and cost discipline, highlighting the April financing, which brought in approximately $195 million in net proceeds. He said the company had $628.4 million in cash, cash equivalents and marketable securities at quarter-end and expects that to last at least into 2028, excluding any product sales. On the P&L, he pointed to lower R&D driven by reduced external costs and lower stock-based compensation, while G&A rose due to commercial build-out, legal costs, and stock-based compensation.
Analysts pressed management on the new HLA/C*05:01 finding, asking whether it applies only to nex-z, how many allele carriers actually had liver enzyme elevations, whether additional prophylaxis or genotyping will be used broadly, and whether the finding could affect labeling or commercial screening. Management said the signal appears specific to nex-z, not lonvo-z, that most C*05:01 carriers did not have severe transaminase elevations, and that they are not changing treatment with additional prophylaxis beyond the existing mitigation strategy; they also said it is too early to know how the finding will appear on label, if at all. On ATTR, analysts asked whether Intellia might change MAGNITUDE’s design after CARDIO-TTRansform and whether the stabilizer background or HLA screening would affect enrollment; management said it wants to review the full CARDIO-TTRansform data first, remains open to design changes, said stabilizer use is running around 80% as expected, and believes HLA screening is confidence-building rather than a drag on enrollment.
The bullish case from this call is that lonvo-z delivered a clean Phase III readout with large attack reduction, meaningful quality-of-life gains, and a safety profile management portrayed as favorable for a one-time therapy. On nex-z, the company said it has resumed Phase III activity, sees a mechanistic explanation for the liver signal, and still believes the drug can show benefit in ATTR based on its rapid and deep TTR suppression and durable control.
The main risk is that nex-z still has an unresolved safety issue: Grade 4 transaminase elevations occurred in less than 1% of patients, and the company’s new HLA finding suggests a subset of patients may face higher risk. Investors also have to wait for full CARDIO-TTRansform data before knowing whether the ATTR program needs design changes, and management did not give data timing for MAGNITUDE. Separately, lonvo-z still needs FDA BLA acceptance and approval before launch, so commercialization remains dependent on regulatory execution.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 95.6%
- Shares Outstanding
- 140.36M
- Float Shares
- 134.16M
of shares held by institutions
354 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for NTLA, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Thomas Richard CarperSenate · DE | Sell | Aug 25, 23 | Filing → |
| Thomas Richard CarperSenate · DE | Buy | May 22, 23 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Sell | Feb 28, 22 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Sell | Oct 29, 21 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Sell | Sep 20, 21 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Sell | Jul 21, 21 | Filing → |
| Thomas Richard CarperSenate · DE | Buy | Nov 20, 20 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Sell | Jan 15, 21 | Filing → |
| Thomas Richard CarperSenate · DE | Buy | Nov 20, 20 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Buy | Nov 18, 20 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Sell | Aug 26, 20 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Buy | Jul 10, 20 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Buy | Jan 14, 20 | Filing → |
| James Mountain InhofeSenate · OK | Sell | Oct 25, 18 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 16.04M | ▲ 626.40K |
| Ark Investment Management LLC | 15.93M | ▼ 950.46K |
| Vanguard Group Inc | 13.01M | ▲ 1.97M |
| State Street Corp | 7.81M | ▼ 1.43M |
| Vanguard Portfolio Management LLC | 7.39M | ▲ 57.27K |
| D. E. Shaw & Co., Inc. | 6.06M | ▼ 378.61K |
| Vanguard Capital Management LLC | 6.04M | ▲ 13.01K |
| Two Sigma Investments, LP | 4.71M | ▼ 524.64K |
| Fmr LLC | 4.69M | ▼ 80.89K |
| Regeneron Pharmaceuticals, Inc. | 3.70M | 0 |
| Amova Asset Management Americas, Inc. | 3.61M | ▲ 713.16K |
| Sumitomo Mitsui Trust Group, Inc. | 3.61M | ▲ 708.09K |
Held by 306 ETFs
Biggest fund positions in NTLA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 2, 26 | LEONARD JOHN M | sell | 9,000 |
| Oct 26, 26 | Marantz Jing L. | other | 275,061 |
| Oct 26, 26 | Marantz Jing L. | other | 199,822 |
| Oct 26, 26 | Marantz Jing L. | other | 0 |
| Oct 2, 26 | Dube Michael P | sell | 1,864 |
| Aug 20, 26 | LEONARD JOHN M | sell | 19,890 |
| Aug 21, 26 | LEONARD JOHN M | sell | 2,785 |
| Jul 22, 26 | Dulac Edward J III | sell | 8,111 |
| Jul 1, 26 | Dube Michael P | sell | 2,641 |
| Jul 2, 26 | Dulac Edward J III | sell | 4,677 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NTLA coverage
Recent articles, reports, and earnings notes.

Biotech’s breakout is a catalyst trade, not a new market leader
Biotech’s sharp outperformance is real, but the rally is rewarding profitable franchises and identifiable catalysts rather than lifting the entire sector. The better opportunity is selective exposure to de-risked pipelines, not indiscriminate bets on biotech as technology’s replacement.
Scribe Therapeutics IPO: What Investors Need to Know
Scribe Therapeutics, Inc. (NASDAQ: SCTX) is expected to list on 2026-07-24 at a price range of $13.00 to $15.00 per share. The company is offering 7,150,000 shares, with a disclosed market cap of $123,337,500. The bull case is a differentiated CRISPR platform aimed at cardiometabolic disease; the bear case is an early-stage story with no approved products and substantial going-concern risk.

Top Gene Editing Stocks: Our 7 Picks for September 2026
A countdown of 7 gene editing stocks, with the top pick revealed last.
Want a deeper read on NTLA?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Intellia Therapeutics Preps Gene-Editing Launch as FDA Review Advances
marketbeat.com · Nov 20
Intellia Therapeutics, Inc. (NTLA) Discusses Lonvo-z Clinical Data and Commercial Launch Preparations in HAE Transcript
seekingalpha.com · Nov 12
Intellia Therapeutics' One-Time HAE Therapy Cuts Attacks 87% in Trial as FDA Decision Nears
marketbeat.com · Nov 12
Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026
globenewswire.com · Nov 12
Intellia Therapeutics to Present at Jefferies Global Healthcare Conference in London
globenewswire.com · Nov 10
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 6
Intellia: Quiet Q3 Earnings As All Eyes Turn To March 2027 Approval Decision
seekingalpha.com · Nov 6
Intellia's Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus
zacks.com · Nov 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.